

Geographic Atrophy

**The study of a new medicine (RO7303359) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)**

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

**Trial Status**  
**Completed**

**Trial Runs In**  
**1 Countries**

**Trial Identifier**  
**NCT04615325 GR42163**

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This clinical trial was done to study a new medicine called, "RO7303359", for the treatment of an eye disease: geographic atrophy secondary to age-related macular degeneration. Men and women at least 50 years old who had the eye disease and met other conditions could take part in this study. Researchers wanted to find out what the side effects of RO7303359 were. They also wanted to find the highest dose that people could tolerate.

**Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)**

Sponsor

**Phase 1**

Phase

**NCT04615325 GR42163**

Trial Identifiers

***Eligibility Criteria:***

**Gender**  
**All**

**Age**  
**>=50 Years**

**Healthy Volunteers**  
**No**